Literature DB >> 16518073

Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells.

Kozo Morimura1, Hisao Yamamura, Susumu Ohya, Yuji Imaizumi.   

Abstract

We examined effects of small and intermediate conductance Ca(2+)-activated K(+) (SK and IK) channel openers, DCEBIO (5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one) and NS309 (3-oxime-6,7-dichloro-1H-indole-2,3-dione), on L-type Ca(2+) channel current (I(Ca)) that was measured in smooth muscle cells isolated from mouse urinary bladder under whole cell voltage-clamp. The I(Ca) was concentration-dependently inhibited by DCEBIO and NS309; half inhibition was obtained at 71.6 and 10.6 muM, respectively. The specificity of NS309 to the IK channel over the Ca(2+) channel appears to be high and higher than that of DCEBIO. DCEBIO and even NS309 may, however, substantially block Ca(2+) channels when used as SK channel openers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518073     DOI: 10.1254/jphs.sc0060011

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  18 in total

1.  Activation of endothelial and epithelial K(Ca) 2.3 calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles.

Authors:  Christel Kroigaard; Thomas Dalsgaard; Gorm Nielsen; Britt E Laursen; Hans Pilegaard; Ralf Köhler; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  KCa 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS.

Authors:  Serge Simonet; Marc Isabelle; Mélanie Bousquenaud; Nicolas Clavreul; Michel Félétou; Christine Vayssettes-Courchay; Tony J Verbeuren
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 3.  Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.

Authors:  Ivica Grgic; Brajesh P Kaistha; Joachim Hoyer; Ralf Köhler
Journal:  Br J Pharmacol       Date:  2009-03-19       Impact factor: 8.739

4.  Openers of small conductance calcium-activated potassium channels selectively enhance NO-mediated bradykinin vasodilatation in porcine retinal arterioles.

Authors:  T Dalsgaard; C Kroigaard; M Misfeldt; T Bek; U Simonsen
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

6.  NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats.

Authors:  E Brøndum; H Kold-Petersen; U Simonsen; Christian Aalkjaer
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

Review 7.  Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.

Authors:  Ralf Köhler; Brajesh P Kaistha; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2010-02       Impact factor: 6.902

8.  Sex differences in endothelial function in porcine coronary arteries: a role for H2O2 and gap junctions?

Authors:  P S Wong; R E Roberts; M D Randall
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Upregulation of intermediate calcium-activated potassium channels counterbalance the impaired endothelium-dependent vasodilation in stroke-prone spontaneously hypertensive rats.

Authors:  Fernanda R C Giachini; Fernando S Carneiro; Victor V Lima; Zidonia N Carneiro; Anne Dorrance; R Clinton Webb; Rita C Tostes
Journal:  Transl Res       Date:  2009-07-31       Impact factor: 7.012

10.  Enhanced glucose tolerance by SK4 channel inhibition in pancreatic beta-cells.

Authors:  Martina Düfer; Belinda Gier; Daniela Wolpers; Peter Krippeit-Drews; Peter Ruth; Gisela Drews
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.